|
1
|
Woo HG, Kim SS, Cho H, Kwon SM, Cho HJ,
Ahn SJ, Park ES, Lee JS, Cho SW and Cheong JY: Profiling of exome
mutations associated with progression of HBV-related hepatocellular
carcinoma. PLoS One. 9(e115152)2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schweitzer A, Horn J, Mikolajczyk RT,
Krause G and Ott JJ: Estimations of worldwide prevalence of chronic
hepatitis B virus infection: A systematic review of data published
between 1965 and 2013. Lancet. 386:1546–1555. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cho H and Kelsall BL: The role of type I
interferons in intestinal infection, homeostasis, and inflammation.
Immunol Rev. 260:145–167. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Terrault NA, Lok ASF, Mcmahon BJ, Chang
KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update
on prevention, diagnosis, and treatment and of chronic hepatitis B:
AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Koumbi L: Current and future antiviral
drug therapies of hepatitis B chronic infection. World J Hepatol.
7:1030–1040. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li H, Gade P, Xiao W and Kalvakolanu DV:
The interferon signaling network and transcription factor
C/EBP-beta. Cell Mol Immunol. 4:407–418. 2007.PubMed/NCBI
|
|
7
|
Mani SKK and Andrisani O: Interferon
signaling during Hepatitis B Virus (HBV) infection and
HBV-associated hepatocellular carcinoma. Cytokine.
124(154518)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liongue C, O'Sullivan LA, Trengove MC and
Ward AC: Evolution of JAK-STAT pathway component: Mechanisms and
role in immune system development. PLoS One.
7(e32777)2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
O'Shea JJ and Plenge R: JAKs and STATs in
immunoregulation and immune-mediated disease. Immunity. 36:542–550.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Elli EM, Baratè C, Mendicino F, Palandri F
and Palumbo GA: Mechanisms underlying the anti-inflammatory and
immunosuppressive activity of ruxolitinib. Front Oncol.
9(1186)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sanachai K, Mahalapbutr P, Choowongkomon
K, Poo-Arporn RP, Wolschann P and Rungrotmongkol T: Insights into
the binding recognition and susceptibility of tofacitinib toward
janus kinases. ACS Omega. 5:369–377. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rashid S, Bibi N, Parveen Z and Shafique
S: Inhibition of Janus kinases by tyrosine phosphorylation
inhibitor, Tyrphostin AG-490. J Biomol Struct Dyn. 33:2368–2379.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Huang C, Cao J, Huang KJ, Zhang F, Jiang
T, Zhu L and Qiu ZJ: Inhibition of STAT3 activity with AG490
decreases the invasion of human pancreatic cancer cells in vitro.
Cancer Sci. 97:1417–1423. 2010.
|
|
14
|
Aue A, Szelinski F, Weißenberg SY,
Wiedemann A, Rose T, Lino AC and Dörner T: Elevated STAT1
expression but not phosphorylation in lupus B cells correlates with
disease activity and increased plasmablast susceptibility.
Rheumatology (Oxford). 59:3435–3442. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hazari S, Chandra PK, Poat B, Datta S,
Garry RF, Foster TP, Kousoulas G, Wakita T and Dash S: Impaired
antiviral activity of interferon alpha against hepatitis C virus 2a
in Huh-7 cells with a defective Jak-Stat pathway. Virol J.
7(36)2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Poat B, Hazari S, Chandra PK, Gunduz F,
Balart LA, Alvarez X and Dash S: SH2 modified STAT1 induces HLA-I
expression and improves IFN-γ signaling in IFN-α resistant HCV
replicon cells. PLoS One. 5(e13117)2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nguyen NV, Tran JT and Sanchez DJ: HIV
blocks Type I IFN signaling through disruption of STAT1
phosphorylation. Innate Immun. 24:490–500. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Spange S, Wagner T, Heinzel T and Krämer
OH: Acetylation of non-histone proteins modulates cellular
signalling at multiple levels. Int J Biochem Cell Biol. 4:185–198.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Krämer OH and Heinzel T:
Phosphorylation-acetylation switch in the regulation of STAT1
signaling. Mol Cell Endocrinol. 315:40–48. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wen D, Wang J, Yan H, Chen J, Xia K, Liu J
and Zhang A: Effect of radix trichosanthis and trichosanthin on
hepatitis B virus in HepG2.2.15 cells. J Nanosci Nanotechnol.
15:2094–2098. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wei J, Tang Bo, Xu B, et al: Construction
of interferon-resistant HBV cell model. Chin Pharm J. 52:832–837.
2017.
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lu YQ, Han JX, Qi P, Xu W, Zu YH and Zhu
B: Rapid quantification of hepatitis B virus DNA by real-time PCR
using efficient TaqMan probe and extraction of virus DNA. World J
Gastroenterol. 12:7365–7370. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shaw T, Bartholomeusz A and Locarnini S:
HBV drug resistance: Mechanisms, detection and interpretation. J
Hepatol. 44:593–606. 2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Férir G, Kaptein S, Neyts J and De Clercq
E: Antiviral treatment of chronic hepatitis B virus infections: the
past, the present and the future. Rev Med Virol. 18:19–34.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Uchibori K, Kasamatsu A, Sunaga M, Yokota
S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H
and Sato N: Establishment and characterization of two
5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J
Oncol. 40:1005–1010. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tran HT, Lim YS and Hwang SB:
Establishment of interferon alpha-resistant hepatitis C virus using
cell culture system. FEBS Lett. 585:409–413. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hou ZH, Han QJ, Zhang C, Tian ZG and Zhang
J: miR146a impairs the IFN-induced anti-HBV immune response by
downregulating STAT1 in hepatocytes. Liver Int. 34:58–68.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li J, Chen F, Zheng M, Zhu H, Zhao D, Liu
W, Liu W and Chen Z: Inhibition of STAT1 methylation is involved in
the resistance of hepatitis B virus to Interferon alpha. Antiviral
Res. 85:463–469. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chen K, Liu J, Liu S, Xia M, Zhang X, Han
D, Jiang Y, Wang C and Cao X: Methyltransferase SETD2-mediated
methylation of STAT1 is critical for interferon antiviral activity.
Cell. 170:492–506, e14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bing Y, Zhu S, Yu G, Li T, Liu W, Li C,
Wang Y, Qi H, Guo T, Yuan Y, et al: Glucocorticoid-induced
S-adenosylmethionine enhances the interferon signaling pathway by
restoring STAT1 protein methylation in hepatitis B virus-infected
cells. J Biol Chem. 289:32639–23655. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Li L, Lei QS, Zhang SJ, Kong LN and Qin B:
Suppression of USP18 potentiates the anti-HBV activity of
interferon alpha in HepG2.2.15 cells via JAK/STAT signaling. PLoS
One. 11(e0156496)2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Krämer OH, Knauer SK, Greiner G, Jandt E,
Reichardt S, Gührs KH, Stauber RH, Böhmer FD and Heinzel T: A
phosphorylation-acetylation switch regulates STAT1 signaling. Genes
Dev. 23:223–235. 2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ginter T, Bier C, Knauer SK, Sughra K,
Hildebrand D, Münz T, Liebe T, Heller R, Henke A, Stauber RH, et
al: Histone deacetylase inhibitors block IFNγ-induced STAT1
phosphorylation. Cell Signal. 24:1453–1460. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gu L, Dagvadorj A, Lutz J, Leiby B,
Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T,
et al: Transcription factor stat3 stimulates metastatic behavior of
human prostate cancer cells in vivo, whereas stat5b has a
preferential role in the promotion of prostate cancer cell
viability and tumor growth. Am J Pathol. 176:1959–1972.
2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Huynh J, Etemadi N, Hollande F, Ernst M
and Buchert M: The JAK/STAT3 axis: A comprehensive drug target for
solid malignancies. Semin Cancer Biol. 45:13–22. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018.PubMed/NCBI View Article : Google Scholar
|
